Oxofulleram topical treatment pilot study in papulopustular rosacea

Phase 2, open-label, single-arm trial of oxofulleram in papulopustular rosacea, sponsored by Soleno Therapeutics. Primary endpoints: Difference in clinical rosacea scores between treated and placebo-treated facial sides at week 12 and Difference in patient self-evaluation scores between treated and placebo-treated facial sides at week 12. Started Jan 2015; status: active, not recruiting.